Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
Stopped The study has been halted because the manufacturer can no longer supply the experimental treatment
Conditions
- MSI
- dMMR Colorectal Cancer
Interventions
- DRUG: Monalizumab/MEDI5257
Sponsor
Assistance Publique - Hôpitaux de Paris